Treatment of achalasia: the short-term response to botulinum toxin injection seems to be independent of any kind of pretreatment

BMC Gastroenterology

HD Allescher¹  M Classen¹  A Meining¹  T Rösch¹  N Weigert¹  E Frimberger¹  P Born¹  M Storr¹ 

[1] Department of Internal Medicine II Technical University of Munich, Munich, Germany

关键词: treatment failure;    balloon dilatation;    myotomy;    achalasia;    botulinum toxin;   

Others  :  1215906
DOI  :  10.1186/1471-230X-2-19

 received in 2002-06-12, accepted in 2002-08-13,  发布年份 2002

【 摘 要 】

Background

It has been suggested that intrasphincteric injection of botulinum toxin (BTX) may represent an alternative therapy to balloon dilatation in achalasia. The aim of the present study was to test the effectiveness of botulinum toxin injections in achalasia patients, as assessed using lower oesophageal sphincter pressure (LOSP) and symptom scores, and to compare the response in patients with different types of pretreatment (no previous treatment, balloon dilatation, myotomy, BTX injection).

Methods

Forty patients who presented with symptomatic achalasia were treated with BTX injection (48 injections in 40 patients). Some of the patients had received prior treatment (seven with myotomy, seven with dilatation and eight with BTX). The symptoms were assessed using a global symptom score (0–10), which was evaluated before treatment, 1 week afterwards, and 1 month afterwards. Manometry was also carried out before and after treatment. Three different selections of patients were studied: all patients; untreated patients; and patients with prior BTX, dilatation, or myotomy.

Results

After BTX injection, there was a significant reduction in LOSP (before, 38.2 ± 11.3 mmHg; 1 week after, 20.5 ± 6.9 mmHg; 1 month after, 17.8 ± 6.8 mmHg; P < 0.001). The global symptom score and symptom subscores (dysphagia, regurgitation, chest pain) were significantly decreased after 1 week and 1 month. When the beneficial effects following BTX injection were compared (untreated vs. pretreated), neither changes in LOSP nor beneficial effects on the symptom scores significantly differed. After 6 months, 67.7% of all treated patients were still in symptomatic remission (subgroups: previously untreated patients, 61.5%, n = 26; prior dilatation, 71.4%, n = 7; prior myotomy, 71.4%, n = 7; prior BTX, 73.9%, n = 8).

Conclusions

BTX injection offers an alternative treatment for achalasia which is safe and can be performed in an outpatient setting. The initial response to BTX, in terms of symptom scores and LOSP, appears to be independent of any prior treatment. A number of patients do not adequately respond to balloon dilatation or myotomy, which are the first-line treatment modalities in achalasia patients. BTX injection can be performed in these patients, and symptomatic benefit can be expected in the same percentages as with BTX injection in untreated patients.

【 授权许可】

   
2002 Storr et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Vaezi MF, Richter JE, Wilcox CM, Schroeder PL, Birgisson S, Slaughter RL, et al.: Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: a randomised trial. Gut 1999, 44:231-239.
• [2]Howard PJ, Maher L, Pryde A, Cameron EW, Heading RC: Fife year prospective study of the incidence, clinical features and diagnosis of achalasia in Edingburgh. Gut 1992, 33:1011-1015.
• [3]Guelrud M, Cohen DO: "Cardiospasm" in achalasia: demonstration of hypersensitivity of the lower esophageal sphincter. Acta Gastroenterol Latinoam 1972, 448:1-7.
• [4]Vantrappen G, Janssens HO, Hellemans J, Coremans G: Achalasia, diffuse esophageal spasm and related motility disorders. Gastroenterology 1979, 76:450-457.
• [5]Aggestrup S, Uddman R, Sundler F, Fahrenkrug J, Hakanson R, Sorensen HR, et al.: Lack of vasoactive intestinal polypeptide in nerves in esophageal achalasia. Gastroenterology 1983, 84:924-927.
• [6]Tottrup A, Knudsen M, Gregersen H: The role of the L-arginine nitric oxide pathway in relaxation of the lower esophageal sphincter. Br J Pharmacol 1991, 104:113-116.
• [7]Barthet M, Mambrini P, Audibert P, Boustiere C, Helbert T, Bertolino JG, et al.: Relationships between endosonographic appearance and clinical or manometric features in patients with achalasia. Eur J Gastroenterol Hepatol 1998, 10:559-564.
• [8]Sezgin O, Ulker A, Temucin G: Sonographic findings in achalasia. J Clin Ultrasound 2001, 29:31-40.
• [9]Vantrappen G, Hellemans J, Deloof W, Valembois P: Treatment of achalasia with pneumatic dilatation. Gut 1971, 12:268-275.
• [10]Vantrappen G, Hellemans J: Treatment of achalasia and related motor disorders. Gastroenterology 1980, 79:144-154.
• [11]Fellows IW, Ogilvie AW, Atkinson M: Pneumatic dilatation in achalasia. Gut 1983, 24:1020-1023.
• [12]Nair LA, Reynolds JC, Parkman HP, Oyyang A, Strom BL, Rosato EF, et al.: Complications during pneumatic dilatation for achalasia or diffuse esophageal spasm. Analysis of risk factors, early clinical characteristics and outcome. Dig Dis Sci 1993, 38:1893-1904.
• [13]Traube M, Dubovik S, Lange RC, McCallum RW: The role of nifedipine therapy in achalasia: results of a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 1989, 84:1259-1262.
• [14]Feussner H, Kauer W, Siewert JR: The surgical management of motility disorders. Dysphagia 1993, 8:135-145.
• [15]Pasricha PJ, Ravich WJ, Kalloo AN: Botulinum toxin for achalasia. Lancet 1993, 341:244-245.
• [16]Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN: Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial. Ann Intern Med 1994, 121:590-591.
• [17]Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN: Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995, 332:774-778.
• [18]Ferrari AP, Siqueira ES, Brant CQ: Treatment of achalasia in Chagas' disease with botulinum toxin. N Engl J Med 1995, 332:824-825.
• [19]Miller LS, Parkman HP, Schiano TD, Cassidy MJ, Ter RB, Dabezies MA, et al.: Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci 1996, 41:2025-2031.
• [20]Storr M, Allescher HD, Rösch T, Born P, Weigert N, Classen M: Treatment of symptomatic diffuse esophageal spasm by injection of Botulinum toxin : A prospective study and long term follow up. Gastrointest endosc 2001, 54:754-759.
• [21]Fishman VM, Parkman HP, Schiano TD, Hills C, Dabezies MA, Cohen S, et al.: Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter. Am J Gastroenterol 1996, 91:1724-1730.
• [22]Culliere C, Ducrotte P, Zerbib F, Metman EH, de Looze D, Guillemot F, et al.: Achalasia: outcome of patients treated by intrasphincteric injection of botulinum toxin. Gut 1997, 41:87-92.
• [23]Al Karawi MA, Ahmed AM, Ghandour Z: Use of botulinum A toxin in achalasia. Endoscopy 1995, 27:217.
• [24]Rollan A, Gonzalez R, Carvajal S, Chianale J: Endoscopic intrasphincteric injection of botulinum toxin for the treatment of achalasia. J Clin Gastroenterol 1995, 20:189-191.
• [25]Khoshoo V, LaGarde DC, Undall JN: Intrasphincteric injection of botulinum toxin for treating achalasia in children. J Pediatr Gastroenterol Nutr 1997, 24:439-441.
• [26]Annese V, Basciani M, Lombardi G, Caruso N, Perri F, Simone P, et al.: Perendoscopic injection of botulinum toxin is effective in achalasia after failure of myotomy or pneumatic dilation. Gastrointest Endosc 1996, 44:461-465.
• [27]Annese V, Basciani M, Perri F, Lombardi G, Frusciante V, Simone P, et al.: Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia. Gastroenterology 1996, 111:1418-1424.
• [28]Pasricha PJ, Rai R, Ravich WJ, Hendrix TR, Kalloo AN: Botulinum toxin for achalasia: long-term outcome and predictors of response. Gastroenterology 1996, 110:1410-1415.
• [29]Kozarek RA, Gelfand MD, Patterson DJ, Brandabur JJ, Bredfeldt JE, Jiranek GE: Randomized prospective trial of 50 vs. 100 IU BOTOX for achalasia – long term follow up. Gastroenterology 1997, 112:A184.
• [30]Allescher HD, Storr M, Seige M, Gonzales-Donoso R, Ott R, Born P, et al.: Treatment of achalasia: Botulinum toxin injection versus pneumatic balloon diolatation – A prospective study with a long-term follow-up. Endoscopy 2001, 33:1007-1017.
• [31]Patti MG, Feo CV, Arcerito M, De Pinto M, Tamburini A, Diener U, et al.: Effects of previous treatment on results of laparoscopic Heller myotomy for achalasia. Dig Dis Sci 1999, 44:2270-2276.
• [32]Bonavina L, Incarbone R, Antoniazzi L, Reitano M, Peracchia A: Previous endoscopic treatment does not affect complication rate and outcome of laparoscopic Heller myotomy and anterior fundoplication for esophageal achalasia. Ital J Gastroenterol Hepatol 1999, 31:827-830.
• [33]Bonavina L, Incarbone R, Reitano M, Antoniazzi L, Peracchia A: Does previous endoscopic treatment affect the outcome of laparoscopic Heller myotomy? Ann Chir 2000, 125:45-49.
• [34]Parkman HP, Reynolds JC, Ouyang A, Rosato EF, Eisenberg JM, Cohen S: Pneumatic dilatation or esophagomyotomy treatment for idiopathic achalasia: clinical outcomes and cost analysis. Dig Dis Sci 1993, 38:75-85.
• [35]Malnick SD, Metchnik L, Somin M, Bergman N, Attali M: Fatal heart block following treatment with botulinum toxin for achalasia. Am J Gastroenterol 2000, 95:3333-3334.